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Abstract
Background: Cases of multiple tumors are rarely reported in China. In our study, a 57-year-old female patient had concurrent
squamous cell carcinoma, mucoepidermoid carcinoma, brain cancer, bone cancer, and thyroid cancer, which has rarely been
reported to date.
Methods: To determine the relationship among these multiple cancers, available DNA samples from the thyroid, lung, and skin
tumors and from normal thyroid tissue were sequenced using whole exome sequencing.
Results:The notable discrepancies of somatic mutations among the 3 tumor tissues indicated that they arose independently, rather
than metastasizing from 1 tumor. A novel deleterious germline mutation (chr22:29091846, G->A, p.H371Y) was identiﬁed inCHEK2, a
Li–Fraumeni syndromecausal gene.Examining the status of this novelmutation in thepatient’shealthy siblings revealed its denovoorigin.
Conclusion: Our study reports the ﬁrst case of Li–Fraumeni syndrome-like in Chinese patients and demonstrates the important
contribution of de novo mutations in this type of rare disease.
Abbreviations: CEA = carcino-embryonic antigen, DNM = de novo mutation, GATK = Genome Analysis Toolkit, Indels = short
insertions and deletions, LFS = Li–Fraumeni syndrome, LFS-L = Li–Fraumeni syndrome-like, NCBI = National Center for
Biotechnology Information, NGS = next-generation sequencing, PCR = Polymerase chain reaction, SCC = squamous cell
carcinoma, SNP = single nucleotide polymorphism, SNV = single nucleotide variant, TCGA = The Cancer Genome Atlas.
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11. Introduction
Currently, researchers’ understanding of the pathogenic and
developmental mechanisms of cancer is improving.[1] The
detection and treatment of cancer is becoming increasingly
precise. The overall cure rate and survival associated with cancer
are signiﬁcantly improved compared with those in the past.[2,3]
However, it is undeniable that the vast majority of cancer
treatments only slow the progress of cancer, and most cancer
patients eventually die from recurrence or metastasis. Given this
situation, we cannot refrain from thinking that all of these
“failures” may be not only due to poor treatment or prognosis
but also due to the incomplete understanding of cancer.
There have been many studies regarding metastatic carcino-
mas, such as brain metastasis from breast cancer,[4] lymph node
metastasis from a primary acral melanoma,[5] and lung
metastases from hepatocellular carcinoma,[6] and the high
similarity of the mutation spectrum and the large frequency of
the shared driver mutations between primary and metastatic
cancers are the major genomic features. In contrast, multiple
primary carcinoma, which could arise in the same organ or
various organs, has rarely been extensively studied because of its
low incidence and high complexity. The most studied multiple
primary carcinoma is Li–Fraumeni syndrome (LFS), which is a
rare disorder that greatly increases the risk of developing several
types of cancer, such as breast cancer, osteosarcoma, and brain
tumors. Identifying and understanding the origin of the causal
mutation in each affected family could provide valuable guidance
for disease diagnosis and prevention.
To date, over half of the cases have been ascribed to germline
mutations of the TP53 tumor suppressor gene, which encodes a
transcription factor (p53) that normally regulates the cell cycle could bind the M-280 beads. Therefore, we could collect the
3. Results
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2and prevents genomic mutations.[7–9] Sequencing the DNA of
several families with LFS showed an autosomal dominant
inheritance of the mutated TP53 gene.[9] Meanwhile, the
frequency of new (de novo) TP53 mutations is estimated to
be at least 7% and may be as high as 20%.[10] Another gene
associated with LFS is CHEK2, which remains somewhat
controversial. The potential correlation between CHEK2 and
LFS was ﬁrst described by Bell et al, in 1999. After that, although
the possibility of CHEK2’s contribution to LFS and Li–Fraumeni
syndrome-like (LFS-L) has been inferred by many researchers,
there was no evidence indicatingCHEK2 is amajor gene involved
in LFS and LFS-L.[11–20] To date, 4 mutations in CHEK2 have
been reported to be associated with LFS or LFS-L: c.1100delC
frameshift mutation, c.470T>C nonsynonymous mutation,
c.1422delT frameshift deletion, and c.983T>C nonsynonymous
mutation,[11,14,15,20] which conﬁrms the relationship between
CHEK2 and LFS. De novo original causal mutations in TP53
have been revealed. However, a causal mutation in CHEK2 has
not been reported in patients with LFS-L.
Spontaneous germline mutation, which occurs due to an error
in copying genetic material or an error in cell division, is
estimated to occur at 1.18108 per position and 1.5 in the
exonic region of the human genome, on average. It plays an
important role in human diseases, and highly penetrant alleles are
under strong negative selection. Such alleles can frequently be
observed as de novo mutations (DNMs) in affected individuals
who harbor neurodevelopmental disorders.[21,22]
LFS-L are considered rare, and, at present, they have been
reported in approximately 500 families, none of which are
in China.[23] Very few studies have utilized next-generation
sequencing (NGS) to obtain genetic proﬁles of the multiple
tumors to pinpoint pathogenesis.[24] In our study, a 57-year-old
female patient had concurrent squamous cell carcinoma (SCC),
mucoepidermoid carcinoma, brain cancer, bone cancer, and
thyroid cancer, which has seldom been reported to date. To verify
the relationship among these cancers and identify the mutations,
we performed an exome-wide genetic investigation on the
different cancerous and normal tissues that we could obtain. We
found that the somatic mutations of these 3 cancer tissues were
notably different, indicating that the multiple carcinomas might
originate independently, instead of occurring by metastasis. By
systematic examination of the genomic information of this
patient and her unaffected siblings, we identiﬁed a de novo
nonsynonymous mutation in CHEK2, the well-known LFS-
associated gene. Thus, by combining the clinical picture with the
genomic information provided by NGS and the literature, we
diagnosed and reported the ﬁrst case of LFS-L in China to have a
TP53-negative and CHEK2-positive mutation.
2. Materials and methods
2.1. Library preparation and whole exome sequencing
We used a QIAamp DNA formalin-ﬁxed and parafﬁn-embedded
tissue kit from Qiagen to collect DNA. The DNA was
subsequently used for library preparations, exon capturing,
and HiSeq2000 sequencing. The library construction of the
HiSeq platform included 5 steps: DNA was sheared to a size of
150 to 200bp and the end repair was performed, after which
adenine and the HiSeq adapter were added and the polymerase
chain reaction (PCR) reaction was carried out. Finally, the library
was ready for hybridization capture. Agilent 44M was the probe
for the whole human exon. There was biotin on the probe, whichwhole exon regions of the DNA. The DNA was ampliﬁed using
PCR, and then the library was sequenced using HiSeq2000 for
type PE91+8+91.
The study was approved by the Ethics Committee of Xijing
Hospital, Fourth Military Medical University.
2.2. Read mapping and germline variation detection
After removing the reads with sequencing adapters and low-
quality reads with >5 ambiguous bases, high-quality reads were
aligned to the National Center for Biotechnology Information
(NCBI) human reference genome (hg19) using BWA (v0.5.9)[25]
with its default parameters. Picard (v1.54) (http://picard.
sourceforge.net/) was used to mark duplicates, and the process
was followed using the Genome Analysis Toolkit (v1.0.6076,
GATK IndelRealigner)[26] to improve the alignment accuracy.
We determined the ﬁnal BAM ﬁle, and we used GATK to detect
the single nucleotide polymorphism (SNP) with the parameters of
-stand_call_conf 50 and -stand_emit_conf 10.0. The short
insertions and deletions (Indels) were also detected by GATK
with the same parameters. Speciﬁc SNPs and Indels were then
ﬁltered for if they met any of the following criteria: 1, the altered
allele support reads <4; 2, genotype quality <20; 3, signiﬁcant
strand bias (P<0.05, Fisher test). All of the SNPs and Indels
were ﬁnally annotated with ANNOVAR (released October 2,
2011).[27]
2.3. Purity estimation and somatic mutation detection
A purity estimation was performed using allele-speciﬁc copy
number analysis of tumors, through which we could not only
accurately dissect the allele-speciﬁc copy number of solid tumors
but also simultaneously estimate and adjust both tumor ploidy
and nonaberrant cell admixture.[28] Somatic point mutations
were detected by VarScan2.2.5 (SAMtools [v0.1.18][29] mpileup
–Q 0 && VarScan2.2.5 somatic –min-coverage 10 –min-
coverage-normal 10 –min-coverage-tumour 10 –min-var-freq
0.1 –min-avg-qual 0)[30] and MuTect.[31] Somatic Indels were
predicted using the GATK Somatic Indel Detector with its default
parameters. All of the high-conﬁdent mutations were obtained
using an in-house pipeline coupled with visual inspection, and
they were then annotated with ANNOVAR.
2.4. Variant validation
We designed oligos to collect the target regions by PCR for
candidate mutation. The PCR products were sequenced using the
ABI 3730 platform.3.1. History and clinical investigation of the case
In October 2011, a 57-year-old female was admitted to our
hospital with a 1-month history of pain in the left iliac waist and
discomfort in the neck area. After a detailed examination, several
nodules were found in the subcutaneous tissue of the trunk of the
patient. Among these nodules, the 1 in the left iliac waist was
found invading the skin, seeming to be a furuncle (Supplementary
Fig. S1, http://links.lww.com/MD/B135). An oval-shaped nodule
was found in her right lateral neck by color Doppler ultrasound
examination. The 6.01.6cm–sized nodule had an ill-deﬁned
margin, a heterogeneous hypoechogenicity, and an incomplete
capsule.
A total thyroidectomy and neck level VI lymph node dissection to date. Before the genetic proﬁling, the clinical diagnosis for
3.2. Whole exome sequencing, variant calling, and tumor
Figure 1. Immunohistochemical staining results of thyroid, skin, and lung tumor samples. (A–C) The thyroid tumor cells in HEX200, which were positive for P63 and
PAS; (D–F) immunohistochemical testing of the maculopapular eruption of the left iliac waist skin revealed the same immunohistochemical proﬁle as that of the
thyroid lesion; (G–I) the immunohistochemical testing of the lung tumor also revealed the same immunohistochemical proﬁle. PAS, periodic acid-Schiff.
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3were performed, and the postoperative pathological examination
showed the presence of a poorly differentiated SCC, which was
positive for P63 (a tumor suppressor protein) (Fig. 1A and C).
Meanwhile, the tumor cells had a scattering of mucus-producing
epithelial components, and immunohistochemical staining
revealed that the tumor cells were positive for periodic acid-
Schiff stain (Fig. 1B). A staging FDG PET/CT scan showed that a
lung nodule, the right frontal lobe of the brain, and multiple
bones were FDG-avid (Supplementary Figs. S2–S4, http://links.
lww.com/MD/B135). In addition, there was a hypermetabolic
focus in the subcutaneous tissue of the trunk (Supplementary
Fig. S5, http://links.lww.com/MD/B135). A ﬁne-needle aspiration
biopsy and immunohistochemical testing on the 5maculopapular
eruptions of left iliac waist and the lung tumor tissue revealed the
same immunohistochemical patterns as the thyroid lesion
(Fig. 1D–I). In the auxiliary examinations, laboratory inves-
tigations indicated a serum carcino-embryonic antigen (CEA)
level of 5.4ng/mL (normal range, 0–5ng/mL), a serum CA153
level of 54.96units/mL (normal range, 0–25units/mL), a serum
CA19-9 level of 558.40units/mL (normal range, 0–29units/mL),
and a serum CA125 level of 407.60units/mL (normal range,
0–35units/mL).
Combined treatment could not be performed because of the
extent of the predicted radiotherapy ﬁeld. As the patient refused
to be treated with chemotherapy or any other targeted therapies,
she received supportive care and was treated with Euthyrox.
The patient’s general condition deteriorated soon after, and she
died 7 weeks after the total thyroidectomy. No autopsy was
performed.
All of this patient’s ﬁrst-degree relatives were healthy.
A case of multiple tumors is rarely reported in China. The
existence of concurrent SCC, mucoepidermoid carcinoma, brain
cancer, bone cancer, and thyroid cancer has been seldom reportedthis case was likely to be synchronous multiple primary lung
cancers, accompanied by brain, skin, and thyroid carcinomas and
osteomas. We could not, however, exclude other possibilities,
such as primary thyroid carcinoma with metastasis or synchro-
nous primary carcinomas in multiple tissues.purity estimation
DNA samples from the thyroid, lung, and skin tumors and from
the normal thyroid tissue were sequenced. The average
sequencing depth of the 4 tissues was approximately 126.34-
fold, and the coverage of the whole exome was 99.5%
(Supplementary Tables S1 and S2, http://links.lww.com/MD/
B134). We detected approximately 30k SNPs for each tissue with
a relatively high dbSNP rate of 98.3%, and the number of Indels
was approximately 2.2k with a dbSNP rate of 72% (Supplemen-
tary Tables S3 and S4, http://links.lww.com/MD/B134). For a
more precise somatic mutation detection excluding the pollution
of normal tissues, we estimated the purity of these 3 tumor tissues
using the SNP data. The purity of these 3 samples was 87%
(lung), 75% (thyroid), and 56% (skin), with a relatively high ﬁt
and reliability score (Supplementary Fig. S6, http://links.lww.
com/MD/B135).
We eventually detected 511, 1341, and 3247 somatic single
nucleotide variants (SNVs) for the thyroid tumor, lung tumor,
and skin tumors, respectively, and the mutation spectrum can be
observed in Supplementary Fig. S7, http://links.lww.com/MD/
B135. The average Ti/Tv was 1.44, and the average NS/SS was
approximately 2.23. We determined 40 (4 in exonic), 50 (2 in
exonic), and 41 (2 in exonic) somatic Indels for the thyroid, lung,
and skin tumors, respectively (Supplementary Tables S10–S12,
http://links.lww.com/MD/B134).
3.3. The genomic proﬁle of the multiple carcinomas T:A->G:C was the highest mutated type in the spectrum of
Figure 2. The molecular-based taxonomy and the relationship among the somatic mutations of the 3 tumors. (A) The vertical axis denotes the 5 tumor types and
subtypes that we selected from the TCGA database, and the lateral axis indicates the 3 tumor types in our study. The size of the dot indicates the number of genes
belonging to a certain tumor type. The Fisher test was performed to investigate the enrichment signiﬁcance of each dot. The asterisk indicates the P value level: (∗)
0.01–0.05, (∗∗) 0.001–0.01, and (∗∗∗) <0.001. (B) The Venn diagram presents the association of the cancer-related somatic mutations among the 3 tumors.
Except for 6 mutations shared between the skin and the lung, no mutation was shared by the 3 tumors.
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4revealed their nonmetastatic nature
We undertook a molecular taxonomy of these three tumor tissues
using the The Cancer Genome Atlas (TCGA) database.[32] Five
tumor types that were likely to be associated with our study were
selected: thyroid carcinoma, small cell lung cancer, skin
cutaneous melanoma, lung squamous, and lung adenocarcino-
ma. The overlappedmutated genes were ﬁltered. After comparing
the tissues from our study to the data we obtained via the above
process, it was determined that the lung cancer tissue in our study
was potentially linked to small cell lung cancer, as the cancers
shared 26 genes with somatic mutations, such as ABCC2,MST1,
and GRM4. The thyroid cancer tissue might be associated with
both thyroid carcinoma and lung adenocarcinoma by 15 and 8
shared mutated genes, separately. The skin tumor could not be
ascribed to skin cutaneous melanoma but was more likely to arise
from small cell lung cancer with 65 common mutated genes, such
as CORIN and ASPM (Fig. 2A). This observation indicated that
the genomic signatures were shared across tumor tissues, and the
genomic proﬁles were not thoroughly identical to their tissue-of-
tumor counterparts.
The relationship of the somatic mutations in these 3 tissues
may potentially explain their evolutionary histories. In the
thyroid tissue, there were 283 SNVs (269 novel) located in the
exonic regions, 214 (205 novel) of which were nonsynonymous
mutations, and 7 SNVs were recorded in Catalogue of Somatic
Mutations in Cancer (v67_241013) (Supplementary Table S6,
http://links.lww.com/MD/B134). In the lung carcinoma tissue,
914 SNVs (724 novel) were in exonic regions; 570 (472 novel)
were nonsynonymous, and 56 SNVs were potentially associated
with cancer (Supplementary Table S7, http://links.lww.com/MD/
B134). In the exonic regions of the skin tumor, there were 2058
SNVs (991 novel), and 1226 (688 novel) were nonsynonymous,
while 162 SNVs located within cancer-related genes were found
(Supplementary Table S8, http://links.lww.com/MD/B134). Thethyroid tumor SNVs, while the C:G->T:A was the maximum
type in the mutation spectrum of both skin and lung tumors
(Supplementary Fig. S7, http://links.lww.com/MD/B135). Next,
we focused on these cancer-related genes and found that there
were no mutations in any of the 3 tumor tissues, but 11 SNVs
were shared by the skin tumor and the lung tumor (Fig. 2B;
Supplementary Table S9, http://links.lww.com/MD/B134). The
tremendous discrepancies of somatic mutations among the 3
tumor tissues in this case suggested that they had arisen from
independent tumor origins rather than metastasis.
3.4. The de novo mutation in CHEK2
To identify the potential pathogenesis of this rare case, we
carefully examined the patient’s genomic information. In total,
we detected 31,840 germline mutations, including 30,022 SNPs
and 1818 Indels, among which 17,606 (440 novel) were located
in exome regions, and 7915 (259 novel) mutations were
nonsynonymous or frameshift mutations. We then focused on
the germline mutations in cancer-related functional genes
(Supplementary Table S5, http://links.lww.com/MD/B134) and
found a novel deleterious heterozygous nonsynonymous muta-
tion (chr22:29091846, G->A, p.H371Y) in CHEK2, which is
not recorded in the 1000 genome database and dbSNP137.
Interestingly, a nonsynonymous 2-bp mutation located nearby
was also related to multiple cancers in the clivar database.[34]
Previous publications showed that LFS and LFS-L can be ascribed
mostly to TP53 and CHEK2 mutations. However, we did not
ﬁnd any germline mutations in TP53, which means that our case
is a TP53-negative and CHEK2-positive LFS-L. CHEK2 is a cell
cycle checkpoint kinase involved in DNA repair, cell death, and
cell cycle control by stabilizing the p53 protein.[33] The mutation
in our case was discovered for the ﬁrst time, and the sorting
tolerant from intolerant predicts that this amino acid substitution
may have damaging effects on the protein function of CHEK2.
The father of the patient passed away prior to the patient extent, demonstrated that the mutation we found is indeed
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